

EFFECTIVENESS AND SAFETY OF INSULIN GLARGINE VERSUS DETEMIR ANALYSIS IN PATIENTS WITH TYPE 1 DIABETES: SYSTEMATIC REVIEW AND META-ANALYSIS

Thales BC SILVA^{1,2}, Paulo HRF ALMEIDA^{1,2}, Vania E ARAÚJO^{1,2,3}, Francisco de Assis ACURCIO^{1,2}, Augusto A GUERRA JÚNIOR^{1,2}, Brian GODMAN^{4,5,6*} and Juliana ALVARES^{1,2}

¹Postgraduate Program in Medicines and Pharmaceutical Services, School of Pharmacy, Federal University of Minas Gerais (UFMG), Brazil. Email: thalescs1@gmail.com; henriqueribeiro.farm@gmail.com; vaniaearaujo@gmail.com; fracurcio@gmail.com; augustoguerramg@gmail.com; Jvalvares@gmail.com

²SUS Collaborating Centre for Technology Assessment and Excellence in Health (CCATES), Federal University of Minas Gerais (UFMG), Belo Horizonte, Minas Gerais Brazil.

³School of Dentistry, Institute of Biological Sciences and Health, Pontifícia Universidade Católica de Minas Gerais (PUCMG), Av. Dom José Gaspar, 500 Coração Eucarístico, Belo Horizonte, Minas Gerais, Brazil.

⁴Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK. Email: Brian.Godman@strath.ac.uk

⁵Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden. Email: Brian.Godman@ki.se

⁶Health Economics Centre, University of Liverpool Management School, Liverpool, UK. Email: Brian.Godman@liverpool.ac.uk

Author for correspondence. Brian Godman: Division of Clinical Pharmacology, Karolinska Institute, Karolinska University Hospital, SE-141 86, Stockholm, Sweden. Email: Brian.Godman@ki.se. Telephone + 46 8 58581068. Fax + 46 8 59581070 and Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4 0RE, United Kingdom. Email: brian.godman@strath.ac.uk. Telephone: +44 141 548 3825. Fax: +44 141 552 2562

(Accepted for publication Therapeutic Advances in Endocrinology and Metabolism – Please keep CONFIDENTIAL)

ABSTRACT

INTRODUCTION: Diabetes mellitus type 1 (DM1) is an autoimmune disease characterized by metabolic destruction of pancreatic cells responsible for insulin production, with treatment based on replacing insulin. Long-acting insulin analogs are indicated for patients with DM1 who exhibit important oscillations of their daily glycemia despite their higher costs. **OBJECTIVE:** To evaluate the effectiveness and safety of two long acting insulins. insulin glargine and detemir in treating patients with DM1. **METHODS:** Systematic review with meta-analysis of observational studies (cohort and registry), available in the database, gray literature and complementary search in Diabetes Care Journal. Outcomes assessed were: glycated hemoglobin concentration, fasting plasma glucose or capillary, occurrence of episodes of severe hypoglycemia and occurrence of nocturnal hypoglycemia. The assessment of methodological quality was performed using the Newcastle score. The meta-analyses were performed on software Review Manager® 5.2. **RESULTS:** Out of 705 publications, 8 cohort studies were included. The quality of these studies was classified as high. In the meta-analysis results regarding episodes of severe hypoglycemia ($p = 0.02$) and fasting glucose ($p = 0.01$) were in favour of detemir. The glycated hemoglobin ($p = 0.49$; $I^2 = 89$) showed high heterogeneity and no statistically significant difference between the two. The meta-analysis of total insulin dose favored glargine ($p = 0.006$; $I^2 = 75$). The rates of nocturnal hypoglycemia (NH) were evaluated only for one study and showed a significant reduction of NH after therapy with detemir, ($p < 0.0001$). **CONCLUSION:** Although some outcomes were favourable to detemir insulin analogue, it has not been possible to identify important differences of effectiveness and safety between the two analogs. These results can help in the current debate on the inclusion of long-acting analogs on the list of reimbursed medicines in the Brazil especially with the recent introduction of insulin glargine biosimilar at considerably lower prices.

Key words: Diabetes Mellitus type 1, glargine, detemir, systematic review, comparative effectiveness.

INTRODUCTION

Diabetes mellitus (DM) is a heterogeneous group of metabolic disorders that includes increased levels of blood glucose resulting from defects in insulin action, on insulin secretion or both. DM is considered a chronic disease with high morbidity and mortality, being one of the leading causes of stroke, myocardial infarction, chronic renal failure, blindness and non-traumatic amputations^(1, 2). Among the types of DM, DM type 1 (DM1) and DM type 2 (DM2) are the most prevalent DM2⁽³⁾.

According to the International Diabetes Federation (IDF), the number of people with DM in the world increased from 108 million in 1980 to 422 million in 2014, and it is estimated that this number will increase to 642 million by 2040. Approximately 80% of patients with DM live in developing countries due to the growth in populations in these countries, population aging, greater urbanization, the prevalence of obesity and progressive sedentariness, as well as increased survival of patients with DM⁽⁴⁾.

Among the therapeutic alternatives available on the market for the treatment of DM1, Neutral Protamine Hagedorn (NPH), which has a profile of intermediate action, is currently considered as standard treatment and the long acting insulin analogs, such as insulin glargine (GLA) and insulin detemir (DET), can be combined with fast-acting insulin for better modulation of pharmacotherapy and glycemic control. GLA and DET allow a more stable profile compared with NPH insulin, without a pronounced peak action that do not require homogenization, leading to possibly more flexible administration^(5, 6).

However, a number of meta analyses and other studies conducted to date do not support the clinical superiority of GLA and DET compared to NPH. In four systematic reviews⁽⁶⁻⁹⁾, there appeared to be no additional clinical benefit of GLA compared with NPH insulin in terms of both effectiveness and side-effects. Similar results were seen observed in a recent cohort study⁽¹⁰⁾ as well as in a recent systematic review comparing the quality of life or patient-reported outcomes between GLA versus NPH insulin⁽¹¹⁾. Despite these and similar studies of long-action insulins versus NPH insulin^(6-10, 12-13), with concerns echoed by the Brazilian Agency of Health Technology Assessment (Comissão Nacional de Incorporação de Tecnologias no SUS - CONITEC)⁽¹⁴⁾ resulting in long-acting insulins not being recommended for inclusion in the list of official reimbursed medicines, GLA has been incorporated into the list of the State Secretary of Health of the State (Secretaria Estadual de Saúde do Estado de Minas Gerais SES/MG) in Brazil. This resulted in public spending of approximately US \$6 million in 2011 for long acting insulins since the difference between the cost of monthly treatment Brazil was 536% for GLA versus NPH, 377% for DET vs. NPH and 34% for GLA vs. DET^(7, 14).

Concerns with the additional costs of long-action insulin analogs has resulted in some countries restricting the indications for funding⁽⁶⁾. In Brazil, SES / MG attempted to restrict the free supply of GLA to patients with DM1 who demonstrate inadequate glycemic control and/or episodes of frequent hypoglycemia following NPH insulin; however, there are still requests from patients with DM2 and/or those patients outside the established criteria⁽¹⁵⁾. Whilst Siebenhofer-Kroitzsch *et al.* also question the clinical relevance of potential minor improvements with insulin analogs versus NPH insulins, they may have a place in selected patients such as those with higher occurrence of nocturnal hypoglycemia⁽¹⁶⁾. It is also worth noting that investment in self-management programs for patients with DM have resulted in sustained clinical gain in terms of glycemic control and a reduced risk of severe hypoglycemia than has been observed with long-action insulins⁽¹⁴⁾. Never-the-less, long-acting insulin analogues are available in Brazil with restrictions on their use in SES / MG.

In view of concerns with cost differentials between different long-acting insulins in some countries, improved kidney function in some patients with the long-acting analogues, although still concerns with their overall benefit versus NPH insulins, and potential differences in effectiveness between the long-acting insulins with differences in action between them ^(6- 8, 17-19), the objective of this study is to evaluate the effectiveness and safety of GLA in comparison to

DET in patients with DM1 through a systematic review and meta- analysis. The results will help inform future decision making in Minas Gerais as well as wider in Brazil and other countries especially as more biosimilars of long-acting insulins become available.

MATERIAL AND METHOD

This review was conducted in accordance with guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA)⁽²⁰⁾ with registration protocol, CRD number 42017054925 in the *International Prospective Register of Ongoing Systematic Reviews* (http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42017054925).

Databases and search strategy

An electronic search was performed in articles published until August to 2017 in databases including MEDLINE (Pubmed), Latin American literature and Caribbean Health Sciences (LILACS), EMBASE and Cochrane Library. Various combinations of terms were used following the peak (population, intervention strategy, comparing, and result): DM1, GLA and DET (Table 1). As a complement to the electronic search, a search was carried out on the references of all included studies as well as in the electronic journal *Diabetes Care* from 2003 to August 2017. We also made a search of grey literature studies included in the bank of theses and dissertations of the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) and Digital Library of Theses and Dissertations at the Federal University of Minas Gerais (UFMG) in case we had missed any important studies.

Table 1 - Search Strategies

Electronic Bases	Search strategies	Files Retrieved
MEDLINE (PUBMED)	((((((((((((((((((("Diabetes Mellitus, Type 1" [Mesh]) OR "Diabetic Ketoacidosis" [Mesh]) OR Insulin-Dependent Diabetes Mellitus [Text Word]) OR Diabetes Mellitus, Insulin-Dependent, 1 [Text Word]) OR Diabetes Mellitus Juvenile-Onset [Text Word]) OR Juvenile-Onset Diabetes Mellitus [Text Word]) OR Diabetes Mellitus, Sudden Onset [Text Word])) OR IDDM [Text Word])) OR Juvenile-Onset Diabetes [Text Word])) OR Diabetes Mellitus Brittle [Text Word])) OR Diabetes Mellitus Ketosis-Prone [Text Word])) OR Diabetes, Autoimmune [Text Word])) OR Autoimmune Diabetes [Text Word])) OR Ketoacidoses, Diabetic [Text Word])) OR Acidosis, Diabetic [Text Word])) AND ((((((((((((((, Insulin Detemir [MeSH Terms]) OR Basal Insulin Detemir [Text Word])) OR Detemir Basal Insulin, [Text Word])) OR Insulin Detemir, Basal [Text Word])) OR NN304 [Text Word])) OR NN-304 [Text Word])) OR Levemir [Text Word])) AND ((((((((((((((Glargine, Insulin [MeSH Terms]) OR Glargine [Text Word])) OR HOE 901 [Text Word])) OR 901, HOE [Text Word])) OR Lantus [Text Word]))	117
EMBASE	#1 ' diabetic ketoacidosis '/exp OR ', diabetic acidosis ' OR ' diabetes ' OR ' acidosis ketoacidosis diabetes ' OR ' diabetes ' OR ' ketosis ' OR ' diabetic acidosis diabetic ketosis ' OR ' insulin dependent diabetes mellitus '/exp OR ' brittle ' OR ' brittle diabetes diabetes mellitus ' OR ' diabetes mellitus type 1 ' OR ' type i diabetes mellitus ' OR ' diabetes mellitus, insulin-dependent diabetes mellitus, ' OR ' type 1 ' OR ' diabetes, type i diabetes mellitus, ' OR ' brittle ' OR ' diabetes, insulin dependent diabetes mellitus ' OR ' juvenile onset ' OR ' diabetes type 1 diabetes type ' OR ' i ' OR ' diabetes, juvenile ' OR ' dm ' OR ' 1 ' early onset diabetes mellitus ' OR ' iddm insulin	472

	dependent diabetes ' OR ' ' OR ' juvenile diabetes ' OR ' juvenile diabetes mellitus ' OR ' juvenile onset diabetes ' OR ' juvenile onset diabetes mellitus ' OR ' ketoacidotic diabetes ' OR ' labile diabetes mellitus ' OR ' type 1 ' OR ' type 1 diabetes diabetes mellitus ' OR ' type i diabetes ' OR ' type i diabetes mellitus ' #2 /exp ' OR ' insulin isophane nph insulin glargine ' #3 /exp ' OR ' abasaglar ' OR ' abasria ' OR ' basaglar ' OR ' insulin glargine ' Or ' hoe 901 ' OR ' hoe901 ' OR ' insulin glargine recombinant ' OR ' insulin [a21 glycine b31 b32 arginine arginine] ' OR ' lantus ' OR ' lantussolostar ' OR ' ly ' OR ' 2963016 ' OR ' ly2963016 ' OR ' optisulin optisulin depot ' OR ' optisulin long ' OR ' toujeo ' #3 /exp ' OR ' detemir insulin levemir ' And cohort analysis /exp ' OR ' controlled clinical trial /exp OR /exp #1 ' AND #2 epidemiology AND #3 AND #4	
COCHRANE LIBRARY	#1 MeSH descriptor: [Diabetes Mellitus, Type 1] explodes all trees #2 MeSH descriptor: [Diabetic Ketoacidosis] explodes all trees #3 Diabetes Mellitus, Insulin-Dependent (Word variations have been searched), Insulin Dependent Diabetes Mellitus #4 (Word variations have been searched) #5 Diabetes Mellitus, Insulin Dependent Juvenile Onset \$ #6-#7 Diabetes Mellitus Type 1 Diabetes #8 Diabetes Mellitus, Type I Diabetes, Autoimmune #9 #10 {or #1-#9} #11 MeSH descriptor: [Insulin Glargine] explodes all trees glargine Lantus #13 #12 #14 {#11-#13 or } #15 MeSH descriptor: [Insulin Detemir] explodes all trees #16, Insulin Detemir (Word variations have been searched) Insulin Detemir Basal #17 (Word variations have been searched) #18 Basal Insulin Detemir,: ti, ab, kw (Word variations have been searched) Levemir #19 #20 {or #15-#19} #21 #14 #20 #22 #10 and #21 and #23 MeSH descriptor: [Cohort Studies] explodes all trees \$ cohort epidemiologic methods #25 #24 #26 controlled clinical trial #27 {or #23 -#26} #28 #22 and #27	109
LILACS	(((((("DIABETIC KETOACIDOSIS") or "DIABETES MELLITUS TYPE 1") or "INSULIN-DEPENDENT DIABETES MELLITUS) or "AUTOIMMUNE DIABETES") or "DIABETES MELLITUS") or "KETOACIDOSIS DIABETICA") or "DIABETES") or "IDDM") or "INSULIN-DEPENDENT DIABETES MELLITUS" [Words] an d (((("GLARGINE") or "LANTUS") or "LANTUS SOLOSTAR") or "GLARGINE" [Words] and (("DETEMIR") or "LEVEMIR") or "INSULIN DETEMIR" [Words]	7

Selection of studies and eligibility criteria

Cohort studies were selected as well as database records of concurrent and non-concurrent patients with DM1. Considered studies included those that assessed GLA vs. DET principally in terms of their effectiveness and safety.

We excluded studies that concentrated on dose comparisons, compared other drugs apart from GLA and DET, pregnant patients, clinical protocols, reviews, case reports, studies in animals, *in vitro* studies, pharmacodynamic studies and/or studies that combined oral antidiabetic medicines with insulin therapy for DM1, as well as studies that included less than 30 participants or follow-up time was less than four weeks, similar to Marra et al.⁽⁷⁾

Data collection and methodological quality assessment

The studies found in the electronic databases were allocated on a single basis to exclude duplicates using the EndNote software programme. Two independent reviewers (TS and PA) evaluated the titles (Phase 1), the abstracts (Phase 2) and the full text (Phase 3). Disagreements were resolved by a third reviewer (VA). The data, including methodological quality, participant information, treatment duration, effectiveness and safety data, were extracted and collected independently with each reviewer on a previously formulated and tested Excel spreadsheet for this purpose.

For the assessment of methodological quality, we used the *Newcastle-Ottawa* scale⁽²¹⁾. This scale was originally developed to evaluate the quality of observational studies. On this scale, each study is evaluated in three dimensions. These include the selection of the study groups, comparability of groups and the calculation of exposure or outcome of interest. The total score of nine is considered to be of high quality. In addition, funding sources have been identified and explored in view of concerns with bias identified in the previous systematic review of Marra *et al.*⁽⁷⁾ and Almeida *et al.*⁽¹¹⁾. The possibility of publication bias was assessed via analysis using a funnel plot.⁽²²⁾ It was considered that there was no conflict of interest in any part of the text if no comment about conflict of interest was found. Conflict of interest refers to sources of funding from pharmaceutical companies or when there was a bond with any of the authors of the study with the pharmaceutical companies. This could include speaker fees or funding for conferences.

Summary of the findings and statistical analysis

The outcomes assessed were the glycated hemoglobin concentration (HbA1c), fasting plasma glucose or capillary and occurrence of episodes of severe hypoglycemia and occurrence of nocturnal hypoglycemia.


The data from the studies were combined using the random effects model of *Review Manager* software version 5.3. The results were presented by the mean difference (MD) for continuous variables with a 95% confidence interval (IC95%). Analyses with a heterogeneity (I^2) greater than 40%, and a p-value chi-square test less than 0.10, were considered as high/significant heterogeneity. Sensitivity analysis was conducted to investigate the causes of the heterogeneity, excluding a study at a time and observed changes in I^2 values and p-value.⁽²²⁾

RESULTS

Included studies

705 publications were found in electronic databases. After deleting duplicates, 609 articles were selected for analysis of the titles and abstracts and 13 for complete reading. After the analysis of the articles using our inclusion criteria, only seven studies were finally selected and the manual search added another publication, totaling eight studies for inclusion in the meta-analysis (Figure 1). Overall, a total of 596 studies were excluded in the first phase after reading titles and abstracts (Figure 1). Following this, as mentioned, 13 studies were progressed to full reading. One study was excluded (Tsujino *et al.*)⁽²³⁾ as the authors had a sample of less than 30 participants. Two studies (Kurtoglu *et al.* and Philips *et al.*)^(24,25) were excluded due to the lack of information and a detailed design of the study, and three studies (Derosa *et al.*, Plavšić *et al.*, and Hopkinson *et al.*)⁽²⁶⁻²⁸⁾ were excluded due to differences in the type of intervention.

Figure 1- Study selection chart



Characteristics of included studies

Of the eight cohort studies retrieved, three were non-concurrent design⁽²⁹⁻³¹⁾ and five, concurrent⁽³²⁻³⁶⁾. Five studies were multicenter studies^(30,32,33,35,36) and three were single centre studies^(29,31,34). The follow-up time ranged from 3.5 to 54 months (Table 2).

Five studies^(30, 33, 34-36) declared conflicts of interest, one⁽³¹⁾ stated the absence of conflicts of interest and two^(39, 32) didn't mention this. Only two studies^(39, 32) did not report funding, five studies^(30, 33-36) were funded by the pharmaceutical industry and a single study⁽³¹⁾ had its own financing. Two studies evaluated only pediatric patients, five studies only adult patients and one study both adults and children. The eight studies included a total of 9,375 patients (Table 2).

With respect to the characteristics of patients, the average age ranged between 12 and 49 years, 56% were men, and the average disease duration ranged from 4 and 21 years.

Table 2 – General characteristics of included studies

Study	Year of publication	Type of study	Number of participants*	Male (%)	Mean Age [†]	Patients	Location of study	Scope	Conflict of interest	Financing	Classification of the duration of the study****	Total score in Newcastle-Ottawa scale
Abali et al. (29)	2014	Cohort Concurrent	117 (85/32)	55	12 ± 3.4	Pediatric	Turkey	SC	NR	NR	Long	7
Haukka et al. (30)	2013	Cohort Concurrent	7110 (3359/7110)	NR	NR	Pediatric and adult	Finland	MC	Yes	Novo Nordisk	Long	6
Kabadi et al. (31)	2008	Cohort Concurrent	45 (24/21)	56	NR	Adult	USA	SC	No	No	Intermediate	7
Jinno et al. (32)	2012	Cohort Concurrent	90 (29/90)	38	11.9 ± 3.8	Pediatric	Japan	MC	NR	Japan Diabetes Foundation	Long	6
Hermansen et al. (33)	2009	Cohort Concurrent	643 (643/643)	39	40.3 ± 15.7	Adult	6 countries **	MC	Yes	Novo Nordisk	Intermediate	7
Preumont et al. (34)	2009	Cohort Concurrent	181 (181/181)	NR	NR	Adult	Belgium	SC	Yes	Novo Nordisk	Intermediate	6
Yenigun et al. (35)	2009	Cohort Concurrent	508 (482/26)	48	NR	Adult	11 countries ***	MC	Yes	Novo Nordisk	Long	7
Dornhorst et al. (36)	2007	Cohort Concurrent	3330 (1665/1665)	NR	NR	Adult	Austria, Czech Republic and Denmark	MC	Yes	Novo Nordisk	Short	5

NR: not reported; No: Declared that there is no conflict of interest. SC = Single center, MC = Multicenter * The value in brackets indicates (n₁/n₂) where, n₁ = the number of participants in the intervention group (glargine), and n₂ = the number of participants in the control group (detemir)

**Czech Republic, United Kingdom, Republic of Ireland, Netherlands, Sweden and Finland.


***Austria, Czech Republic, Denmark, Finland, Germany, Ireland, Israel, Netherlands, Sweden, Turkey and United Kingdom

****Studies with follow-up time of up to 3 months were classified as short, 3 to 6 months as an intermediate and more than 6 months as long.

Methodological quality

No studies obtained the maximum score of nine stars on the Newcastle-Ottawa scale (Table 2). Four studies scored seven, three six, and one scored five. The quality of the included studies was ranked as high. There was asymmetry in the funnel plot (Figure 2) for the HbA1c outcome, suggesting an influence of publication bias.

Figure 2 – Funnel plot of MD in HbA1c. MD mean difference, SE standard error



Summary of the findings

To assess the effectiveness and safety of the different long-acting insulins in meta-analysis, the following outcomes were included: HbA1c, severe hypoglycaemia, total dose of insulin and fasting glucose. As for the outcome of events of NH, we described only the results presented in each study since they did not provide data in pairs that could be combined in a meta-analysis.


Table 3 - Result of meta-analysis

Outcome	Number of studies	Participants	Estimated effect (IC 95%)	I ² (%)	P-Value *
1. HbA1c [%]	6	5971	0.10 [-0.17, 0.37]	89	0.49
1.1 Studies of intermediate duration	3	1696	-0.20 [-0.77, 0.38]	91	0.51
Long-term studies	2	945	0.43 [-0.64, 0.22]	0	< 0.0001
Studies of short duration	1	3330	0.40 [0.30, 0.50]	-	< 0.00001
1.2 With Conflict of interest	4	5806	0.30 [0.12, 0.47]	0	< 0.00001
Without conflict of interest	2	165	-0.45 [-1.43, 0.52]	86	0.0007
2. Severe hypoglycemia [ep/pes-year]	2	8598	0.68 [0.26, 1.10]	8	0.002
3. total Dose of insulin [U/Kg/day]	4	1489	-0.07 [-0.12,-0.02]	75	0.006
4. Fasting Glucose [mmol/L]	5	5816	0.64 [0.13, 1.15]	89	0.01

* P-value of the test for general effect


HbA1c analysis were included six studies^(29, 31, 33-36). The results did not favor any of the two long acting insulins ($p = 0.49$), with an average difference of 0.10 (CI:-0.17, 0.37, $p < 0.00001$; $I^2 = 89\%$), and significant heterogeneity (Figure 3).

Figure 3 - Meta-analysis Glycated Hemoglobin (%)




In the meta-analysis that assessed the total dose of insulin administered, four studies were included^(29, 31, 34, 35). There was a statistically significant difference favoring GLA ($p = 0.006$) in -0.07 (CI:-0.12, 0.02, $p = 0.007$; $I^2 = 75\%$) and with a significant heterogeneity (Figure 4).

Figure 4 – Meta-analysis full dose of insulin (U/kg/day)




In the meta-analysis that assessed the occurrence of severe hypoglycemia, only two studies were included^(30,36). The data showed a statically significant difference favoring DET ($p = 0.002$), with a difference of average 0.68 (CI: 0.26, 1.10, $p = 0.30$; $I^2 = 8\%$) (Figure 5).

Figure 5 – Meta-analysis severe hypoglycemia (episodes/person-year)



Five studies were included when evaluating fasting glucose levels⁽³²⁻³⁶⁾. The result was statistically significant favoring DET ($p = 0.01$), with an average difference of 0.64 (CI: 0.13, 1.15, $p < 0.00001$; $I^2 = 89\%$) with a high heterogeneity (Figure 6).

Figure 6 - Meta-analysis fasting glucose (mmol/L)



Nocturnal hypoglycemia events were assessed in the meta-analysis because the studies did not present data that could be combined. In the study of Yenigun *et al*⁽³⁵⁾ nocturnal hypoglycemia events per patient-year were reduced to 10.01 with GLA once a day and to 3.77 with DET once a day ($p < 0.0001$). Dornhost *et al*⁽³⁶⁾ noted a decrease of 10.1 nocturnal hypoglycemia events per patient-year with GLA vs. DET ($p < 0.0001$).


In the study of Haukka *et al*⁽³⁰⁾, DET presented a lower risk of 13.1% (1.0%), 29.6% -23.6 (-47.8%) and 17.9 5.1% (3.6-30.1%) for the occurrence of the first recurring hypoglycemia as well as hypoglycemia and coma hypoglycemic ($p = 0.034$, $p = 0.021$, $p = 0.016$), respectively, versus GLA.

Analysis of Subgroups

The outcome of HbA1c was also evaluated in two subgroups: the time of follow-up and the presence of conflict of interest.


Studies classified as intermediate follow-up^(31,33,34) (Table 2) had not statistically significant findings ($p = 0.51$) (MD = -0.19; IC: -0.74, 0.37, $p < 0.0001$; $I^2 = 93\%$). In longer duration studies^(29, 35), the difference of the average was estimated at 0.43 (IC: 0.22, 0.64, $p = 0.36$; $I^2 = 0\%$) favouring DET. When consolidated, an estimate of the difference of the average was 0.10 (CI: -0.17, 0.37, $p < 0.00001$; $I^2 = 89\%$) with high heterogeneity and did not favor either of the two long acting insulin. Sensitivity analyses excluding one study⁽³¹⁾ affected the outcome favoring DET ($p = 0.0005$) and decreasing the heterogeneity for $I^2 = 61\%$ (Table 3, Figure 7).

Figure 7 - Meta-analysis Glycated Hemoglobin (%) - subgroup of the study duration



In the subgroup without studies of conflicts of interest^(29, 31), there were no statistically significant differences in HbA1c (DM = -0.45, CI = -1.43, 0.52, $p = 0.02$, $I^2 = 82\%$). In the subgroup with studies of conflicts of interest⁽³³⁻³⁶⁾, there was an estimated average difference of 0.30 (CI: 0.14, 0.46, $p = 0.01$, $I^2 = 72\%$) favoring DET. The total results showed no statistically significant difference between the two long-acting insulins with a mean difference of 0.10 (CI: -0.17, 0.37, $p < 0.00001$, $I^2 = 89\%$) with high heterogeneity (Table 3, Figure 8). The exclusion of any studies in the sensitivity analyzes affected the direction of the result.

Figure 8 - Meta-analysis Glycated Hemoglobin (%) - conflict of interest subgroup



DISCUSSION

Faced with a chronic disease such as DM1, which requires that patients take care of themselves over a long period of time, it is necessary to outline a plan of action which can be modified when new clinical findings and/or laboratory results justify such modification. Intensive therapy, bringing together multiple daily injections and self-monitoring, aiming to achieve improved glycemic control, are considered the optimal treatment for the DM1 to reduce of the risk of complications. Strict control of DM1 can delay the progression of chronic microvascular

complications in approximately 50% of cases, which makes the treatment of DM1 cost-effective⁽³⁷⁾.

The availability of long-acting insulins adds to the armamentarium where there are concerns with control of HbA1c and hypoglycaemia with current approaches. The findings from our meta-analysis of Hb1Ac found no differences between the two long-acting insulins (GLA and DET) in terms of glycemic control. Similar results were also described in randomized clinical trials (RCTs) and systematic reviews that compared GLA, DET and NPH insulin^(9-12, 33,34,38). Swinnen *et al* in their earlier systematic review of RCTs comparing GLA vs. DET also showed that glycemic control, as measured by the Hb1Ac, did not differ statistically significant between the different long-acting insulins⁽³⁹⁾, adding to our findings.

When evaluating the results of HbA1c, the subgroup of studies free of conflict of interest did not show statistically significant difference between GLA vs. DET. In the subgroup with conflicts of interest, the results favoured DET, but the reference values for HbA1c control, recommended by the American Diabetes Association as below 7.0%, were not achieved⁽³⁷⁾. Bekelman *et al* claim that financial relations between the industry, researchers and academic institutions, can lead to favorable results for the sponsor, which can compromise patient's subsequent welfare⁽⁴⁰⁾. Similar results were found in a previous meta-analysis⁽¹⁰⁾.

Two studies were included in the meta-analysis of doses used, with the results favorable to GLA. A daily dose (possibly two) is a basal scheme, with lispro/asparte/gulisin before each meal or, in the case of unpredictability of food intake (common in children), immediately after the meal. Despite GLA and DET having very similar absorption curves, there are differences between the two insulins, as a side-chain fatty acid promotes the formation of hexamers in the injection site, decreasing the absorption of DET and prolonging even further its action, indicating that the doses of DET should be about 30% higher than the doses of NPH used previously⁽⁴¹⁾. On the other hand, there seems to be less intra-individual variation with the use of DET compared with GLA and NPH⁽⁴²⁾.

The result of the meta-analysis of severe hypoglycemia involving 8598 patients showed statistically significant results favouring DET. Singh *et al*⁽⁸⁾ showed that the DET reduced the risk of occurrence of episodes of severe hypoglycemia and nocturnal in relation to NPH, an advantage not seen with GLA insulin. Pieber *et al*.⁽⁴³⁾ showed that the use of DET is equally effective in glycemic control versus GLA in patients with DM1, but with less daytime hypoglycaemia or severe hypoglycemia. However, in relation to the control of episodes of hypoglycemia (any episode of hypoglycemia), the meta-analysis by Monami *et al*⁽⁹⁾ showed that the incidence of any event of hypoglycemia was equal among the long-acting insulin analogs and NPH insulin.

In this context, self-management is integral to the control of DM1 as it allows patients to assess their individual response to therapy with insulin as well as monitor whether blood glucose targets are being effectively achieved, and may be useful in preventing hypoglycemia or hyperglycemia symptoms and therapeutic adjustment⁽⁴⁴⁾.

The results of the meta-analysis of fasting glucose also favored DET, with lower values in patients treated with DET when compared to the GLA. However, recent studies have questioned this parameter to monitor the glycemic control of patients, because it reflects a one-time non-recurring measure, at the time of blood collection⁽³⁷⁾.

Although some results favored the DET, in most cases, the therapeutic goal for glycemic control was not achieved in the groups of patients monitored. This can be due to barriers which the disease imposes, such as the occurrence and the fear of hypoglycemic events, the complexity of daily treatment, the need for self-monitoring and frequent adjustments of insulin doses and because in routine clinical care the results from long-acting insulin analogs may not duplicate those observed in RCTs⁽⁴⁻⁸⁾. Consequently, the choice of long-acting insulin analogs should be based in the individual characteristics of the patient, the effectiveness of existing therapies and any cost differential between the different insulins.

Currently, the annual costs of treating people with DM represents approximately 12% of total health expenditure in the world⁽⁴⁾. Whilst not the subject of this review, the cost differential between GLA, DET and NPH insulins must be considered especially in healthcare systems striving for, or currently attaining, universal access within finite resources. A study conducted by the Canadian Agency for Drugs and Technologies in Health (CADTH) compared the cost-effectiveness of GLA and DET with NPH in patients with DM1 and DM2, and noted that the long-action analogs are not cost effective and that the substitution of NPH by DET and GLA in patients with DM1 would be costly to the Canadian health system⁽¹³⁾. Evaluations carried out in the United Kingdom estimated savings of up to US \$836 million over a decade with greater use of NPH versus long-action analogs⁽⁴⁵⁾. The savings would have been higher if you take into account the Brazilian perspective, since in the United Kingdom the cost differential between long-action analogs and NPH insulin is lower than the 536% differential that currently exists in Brazil.

However in 2017, the National Agency of Sanitary Vigilance (Agência Nacional de Vigilância Sanitária - ANVISA) of Brazil registered GLA biosimilar (Abasagar), with its price determined by the Regulation of the Marketing of Medicines (Câmara de Regulação do Mercado de Medicamentos - CMED) at 70% lower than originator GLA and 45% lower than DET^(46,47). This systematic review and meta analysis, along with other studies and economic analyses, can help health authorities, and those responsible for the coordination of health programs and services within finite resources in Brazil and other countries with universal healthcare, re-evaluate the possible incorporation of different long-action analogs into the list of publicly funded of medicines, as well as potentially help with price negotiations. In Germany after the authorities recommended the exclusion of short acting insulin analogs since there were no data demonstrating superiority over NPH insulin to justify significantly higher prices, the manufacturers introduced significant price to keep them reimbursed⁽⁴⁸⁾. A similar approach could be adopted in Brazil, as well as in the State of Minas Gerais, as more biosimilar long-acting analogues become available with limited differences between them in terms of their clinical effectiveness and safety, and potentially considerable price reductions versus the originators. These are considerations for the future.

We acknowledge there are limitations of this systematic review. It included cohort studies with the intrinsic selection bias of observational studies. There were also differences in the number of participants between the groups and the monitoring period between studies. Nevertheless observational studies generally have greater statistical power and a population closer to the "real world", i.e. with broader inclusion criteria, without exclusion of patients potentially more serious and without the strict limits of RCTs.

The selected data to the meta-analysis can also be influenced by publication bias, that is, the tendency of the published results is systematically different from reality. An analysis of clinical trials registered on the basis of Protocol ClinicalTrial.gov revealed that less than 70% of studies are published⁽⁴⁹⁾. The non-publication of results may be due to the decision of the author or the funder of the study where there are unfavourable findings; alternatively, less interest from publishers of scientific journals where there are negative results or results without statistical significance. The publication bias, with the selection of favorable results, can also influence the data used in meta-analyses⁽⁴⁰⁾. To minimize the potential for publication bias, a comprehensive search was conducted including gray literature and complementary searches. However, in this systematic review analysis of the funnel plot we found asymmetry. Most of the studies though showed great precision, usually performed with large samples, and distributed symmetrically in the upper part of the funnel. Only the study by Kabadi *et al.*⁽³¹⁾ showed lower precision, located on the outside of the funnel. Another limitation of our meta analysis was the small number of studies included in the review and the lack of complete and accurate information for inclusion in the quantitative analyses as few published studies made direct comparison between GLA vs. DET, which hindered the explanation of the sources of heterogeneity. In relation to the sensitivity analysis, the inclusion and exclusion of studies in each comparison did not changed the direction of the most outcome measures, without significant changes in heterogeneity, with exception of Kabadi *et al.*⁽³¹⁾ which when deleted the analysis changed the direction of the results that favor the DET. Overall, the scarcity of studies comparing GLA vs. DET, and the absence of other analysis with "real-world" data, make it difficult to fully compare the results.

Never-the-less, we believe our findings are robust providing direction to the authorities in Brazil and wider.

CONCLUSION

Although some results are favourable to DET, it has not been possible to identify differences in effectiveness and safety compared to the GLA. This would require new long-term studies and better methodologies. Never-the-less, our findings suggesting limited clinical differences between the different long-acting insulin analogs can help in the current debate on the inclusion of long-acting analogs, including biosimilars, in the official list of medicines reimbursed in the Brazil. The market entry of GLA and other future biosimilars can assist with price negotiations and subsequent listing including potentially expanding population groups. It is important to note though that for a good glycemic control, therapeutic interventions should be accompanied by continuous monitoring of blood glucose, dietary interventions and effective education. These are considerations for the future.

Acknowledgements

The research was supported by the Research Group in Pharmacoepidemiology UFMG. This research is an integral part of the research project 'Comparative Clinical Effectiveness and cost-effectiveness of Glargine insulin analog for the treatment of patients suffering from Diabetes Mellitus' with financial support from the National Scientific and Technological Development Council in Brazil (CNPq).

The write-up was in part supported by a Newton Advanced Fellowship awarded to Professor Augusto Afonso Guerra Junior by the Academy of Medical Sciences, through the UK Government's Newton Fund programme. All named authors take responsibility for the integrity of the work as a whole, and have given final approval for the version to be published.

REFERENCES

1. United States Renal Data System. International Comparisons. In United States Renal Data System. 2014 USRDS annual data report: Epidemiology of kidney disease in the United States. Bethesda (MD): National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases 2014; 188–210.
2. Moxey PW, Gogalniceanu P, Hinchliffe RJ, et al. Lower extremity amputations – a review of global variability in incidence. *Diabetic Medicine* 2011; 28:(10)1144–53
3. De Oliveira GL, Guerra Junior AA, Godman B, Acurcio FA. Cost-effectiveness of vildagliptin for people with type 2 diabetes mellitus in Brazil; findings and implications. *Expert review of pharmacoeconomics outcomes research*. 2017;17(2):109-19.
4. International Diabetes Federation. *IDF Diabetes Atlas*. 7th ed. Brussels: International Diabetes Federation; 2015. Available at: <http://www.diabetesatlas.org/>
5. Plank J, Bodenlenz M, Sinner F, Magnes C, Görzer E, Regittnig W, et al. The double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. *Diabetes care*. 2005;28(5):1107-12.
6. Caires de Souza AL, de Assis Acurcio F, Guerra Junior AA, Rezende Macedo do Nascimento RC, Godman B, Diniz LM. Insulin glargine in a Brazilian state: should the government disinvest? An assessment based on a systematic review. *Applied health economics and health policy*. 2014;12(1):19-32.
7. Marra LP, Araújo VE, Silva TBC, Diniz LM, Guerra Junior AA, Acurcio FA, et al. Clinical Effectiveness and Safety of Analog Glargine in Type 1 Diabetes: A Systematic Review and Meta-Analysis. *Diabetes Ther*. 2016 Jun;7(2):241–58.
8. Singh SR, Ahmad F, Lal A, Yu C, Bai Z, Bennett H. Efficacy and safety of insulin analogs for the management of diabetes mellitus: a meta-analysis. *CMAJ*. 2009;180(4) :385-397
9. Monami M, Marchionni N, Mannucci E.. Long-acting insulin analogs vs NPH human insulin in type 1 diabetes: a meta-analysis. *Diabetes Obes Metab*. 2009;11(4):372-8

10. Marra LP, Araújo VE, Oliveria GCC, Diniz LM, Guerra Júnior AA, de Assis Acurcio F et al. The clinical effectiveness of insulin glargine in patients with type 1 diabetes in Brazil: findings and implications. *J Comp Eff Res*. 2017 Sep;6(6):519-527.
11. Almeida PHRF, Silva TBC, de Assis Acurcio F, Guerra Junior AA, Araujo VE, Diniz LM, et al. Quality of Life of Patients with Type 1 Diabetes Mellitus Using Insulin Analog Glargine Compared with NPH Insulin: A Systematic Review and Policy Implications. *The patient*. 2018
12. Tunis SL, Minshall ME, Conner C, McCormick JI, Kapor J, Yale JF, Groleau D. Cost effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modeling analysis. *Curr Med Res Opin*. 2009; 25(5):1273-84.
13. CADTH. COMPUS. Long-Acting Insulin Analogs for the Treatment of Diabetes Mellitus: Meta-analyses of Clinical Outcomes. 2008; Issue 1, Volume 2. Available at: <http://www.cadth.ca>.
14. Rede Brasileira de Avaliação de Tecnologia em Saúde (Brazilian Network for Health Technology Assessment): Boletim Brasileiro de Avaliação de Tecnologias em Saúde (Brazilian Bulletin of Health Technology Assessment). Insulina Glargina e Insulina Detemir no Controle da Diabetes Mellitus Tipo 1 (Glargine insulin and detemir insulin: the control of type 1 diabetes mellitus), 2010. Available at URL: http://bvsms.saude.gov.br/bvs/ct/pdf/brats2010_n13.pdf (Accessed 5 December 2017)
15. RESOLUÇÃO SES Nº 1761 DE 10 DE FEVEREIRO DE 2009. Available at URL: http://www.saude.mg.gov.br/images/documentos/resolucao_1761.pdf (Accessed 14 December 2017)
16. Siebenhofer-Kroitzsch A, Horvath K, Plank J. Insulin analogues: too much noise about small benefits. *CMAJ*. 2009;180(4):369-70
17. Permsuwan U, Thavorn K, Dilokthornsakul P, Saokaew S, Chaiyakunapruk N. Cost-effectiveness of insulin detemir versus insulin glargine for Thai type 2 diabetes from a payer's perspective. *Journal of medical economics*. 2017;20(9):991-9
18. Hasslacher C, Kulozik F, Lorenzo Bermejo J. Treatment with insulin analogs, especially Glargine and Lispro, associates with better renal function and higher hemoglobin levels in Type 1 diabetic patients with impaired kidney function. *Therapeutic advances in endocrinology and metabolism*. 2016;7(4):166-77
19. Zhang T, Lin M, Li W, Fan X, Du T, Zhao Y, et al. Comparison of the Efficacy and Safety of Insulin Detemir and Insulin Glargine in Hospitalized Patients with Type 2 Diabetes: A Randomized Crossover Trial. *Adv Ther*. 2016;33(2):178-85
20. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. *BMJ* 2009;21: 339:b2700.
21. Hartling L, Hamm M, Milne A, et al. Validity and reliability tests between evaluator of quality assessment tools [internet]. Appendix E, decision rules for application of the Newcastle-Ottawa Scale. Research and Quality Agency in health (us), Rockville, Maryland (MD). Available at URL: <http://www.ncbi.nlm.nih.gov/books/NBK92291/> (Accessed 1 September 2016)
22. HIGGINS, J. P. T.; GREEN, S. Cochrane handbook for systematic reviews of interventions [Internet]. Version 5.2.0 [updated June 2017]: The Cochrane Collaboration, 2017 [accessed 05.02.2018].
23. Tsujino D, Nishimura R, Morimoto A, Tajima N, Utsunomiya K. The crossover comparison of glycemic variations in Japanese patients with type 1 diabetes receiving insulin glargine versus insulin detemir twice daily using continuous glucose monitoring (CGM): J COLLECTION (Jikei COmparison of Lantus and LEvemir with Cgm is Thinking Insulin Optimization). *Diabetes Technol Ther*. 2012 Jul;14(7):596-601

24. Kurtoglu S, Atabek ME, Dizdarer C, Pirgon O, Isguven P, Emek S; PREDICTIVE Turkey Study Group. Insulin detemir improves glycemic control and reduces hypoglycemia in children with type 1 diabetes: findings from the Turkish cohort of the PREDICTIVE observational study. *Pediatr Diabetes*. 2009 Sep;10(6):401-7
25. Philips JC, Scheen AJ. Insulin detemir in the predictive study: results in patients with type 1 diabetes in the Belgian cohort. [Article in French]. *Rev Med Liege*. 2009;64(3):124-30.
26. Derosa G, Franzetti I, Querci F, Romano D, D'Angelo A, Maffioli P. Glucose-lowering effect and glycaemic variability of insulin glargine, insulin detemir and insulin lispro protamine in people with type 1 diabetes. *Diabetes Obes Metab*. 2015;17(6):554-9
27. Plavšić L, Mitrović K, Todorović S, Vuković R, Milenković T, Zdravković D. Glycaemic control and prevalence of hypoglycaemic events in children and adolescents with type 1 diabetes mellitus treated with insulin analogs. *Vojnosanit Pregl* 2014; 71(9): 817–820
28. Hopkinson HE, Jacques RM, Gardner KJ, Amiel SA, Mansell P. Twice - rather than once - daily basal insulin is associated with better glycaemic control in Type 1 diabetes mellitus 12 months after skills - based structured education in insulin self - management. *Diabet Med*. 2015;32(8):1071-6
29. Abalı S, Turan S, Atay Z, Güran T, Haliloğlu B, Bereket A. Higher insulin detemir doses are required for the similar glycemic control: comparison of insulin glargine and detemir in children with type 1 diabetes mellitus. *Pediatr Diabetes*. 2015;16(5):361-6
30. Haukka J, Hoti F, Erästö P, Saukkonen T, Mäkimattila S, Korhonen P. Evaluation of the incidence and risk of hypoglycemic coma associated with selection of basal insulin in the treatment of diabetes: Finnish register linkage study. *Pharmacoepidemiol Drug Saf*. 2013;22(12):1326-35
31. KABADI UM. Deleterious outcomes after abrupt transition from insulin glargine insulin detemir to in patients with type 1 diabetes mellitus. *Clin Drug Investig*. 2008;28(11):697-701
32. Jinno K, Urakami T, Horikawa R, Kawamura T, Kikuchi N, Kikuchi Tet al. Usefulness of insulin detemir in Japanese children with type 1 diabetes. *Pediatr Int*. 2012;54(6):773-9
33. HERMANSEN K, DORNHORST A, SREENAN S. Observational, open-label study of type 1 and type 2 diabetes patients switching from human insulin to insulin analogue basal-bolus regimens: insights from the PREDICTIVE study. *Curr Med Res Opin*. 2009;25(11):2601-8
34. Preumont V, Buysschaert M, De Beukelaer S, Mathieu C. Insulin detemir in routine clinical practice: the 26-week follow-up in type 1 diabetic patients from the Belgian PREDICTIVE cohort. *Acta Clin Belg*. 2009;64(1):49-55
35. YENIGUN M, HONKA M. Switching patients from insulin glargine-based basal-bolus regimens to a once daily insulin detemir-based basal-bolus regimen: results from a subgroup of the PREDICTIVE study. *Int J Clin Pract*. 2009 Mar;63(3):425-32
36. Dornhorst A, Lüddecke HJ, Sreenan S, Koenen C, Hansen JB, Tsur A, Landstedt-Hallin L.. Safety and efficacy of insulin detemir in clinical practice: 14 - week follow - up data from type 1 and type 2 diabetes patients in the PREDICTIVETM European cohort. *Int J Clin Pract*. 20;61(3):523-8
37. American Diabetes Association (ADA). Standards of medical care in diabetes. Position statement. *Diabetes Care*. 2017; 40(1): S1–S135.
38. HELLER S, Koenen S, Bode B. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial.. *Clin Ther*. 2009;31(10):2086-97
39. Swinnen SG, Simon AC, Holleman F, Hoekstra JB, Devries JH. Insulin detemir versus insulin glargine for type 2 diabetes mellitus. *Cochrane Database Syst Rev*. 2011;(7):CD006383
40. BEKELMAN JE, LI Y, GROSS CP. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. *JAMA*. 2003;289(4):454-65.

41. Kurtzhals P, Havelund S, Jonassen I, Markussen J.. Effect of fatty acids and selected drugs on the albumin binding of a long-acting, acylated insulin analogue. *J Pharm Sci.* 1997;86(12):1365-8.
42. Hermansen K, Madsbad S, Perrild H, Kristensen A, Axelsen M. Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy.. *Diabetes Care.* 2001;24(2):296-301.
43. Pieber TR, Treichel HC, Hompesch B, Philotheou A, Mordhorst L, Gall MA, Robertson LI.. Comparison of insulin detemir and insulin glargine in subjects with type 1 diabetes using intensive insulin therapy. *Diabet Med.* 2007;24(6):635-42
44. Wolpert HA. The nuts and bolts of achieving end points with realtime continuous glucose monitoring. *Diabetes Care.* 2008; 31 (suppl 2):S146-S9.
45. Holden SE, Poole CD, Morgan CL, Currie CJ.. Evaluation of the incremental cost to the National Health Service of prescribing analogue insulin. *BMJ Open.* 2011;1(2):e000258
46. Diabetes mellitus type 1 and type 2: insulin glargine biosimilar (Abasaglar) - Evidence summary [ESNM64]. Available at URL: <https://www.nice.org.uk/advice/esnm64/chapter/Key-points-from-the-evidence>.
47. MAXIMUM PRICES OF MEDICINAL PRODUCTS BY ACTIVE SUBSTANCE, Câmara de Regulação do Mercado de Medicamentos- CMED. Available atURL: <http://portal.anvisa.gov.br/consulta-lista-de-preco-de-medicamento> (Accessed 13 December 2017)
48. IQWiG Reports–Commission No. A05-02. Rapid-acting insulin analogues in the treatment of diabetes mellitus type 1 [article online], 2007. Available at URL: www.iqwig.de/download/A0502_Abschlussbericht_Kurzwirksame_Insulinanaloga_bei_Diabetes_mellitus_Typ_1.pdf (Accessed 13 December 2017)
49. Ross JS, Tse T, Zarin DA, Xu H, Zhou L, Krumholz HM. Publication of NIH funded trials registered in ClinicalTrials.gov: cross sectional analysis. *BMJ.* 2012;344(d7292):1–10